Search
Lopinavir
go.drugbank.com/drugs/DB01601ApprovedInvestigationalcannot be cleaved, thus preventing the activity of the HIV-1 protease. … [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's
Mixtures: LOPINAVIR E RITONAVIR MYLAN, LOPINAVIR E RITONAVIR MYLANCategories: Antivirals used in combination for the treatment of HIV infectionsTacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. … It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex.
Products: T-INMUN ®0.03% UNGUENTO, T-INMUN ® 0.1 % UNGUENTOBenzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigational[L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564] … [A264454] As a prodrug, benzagalantamine remains inert as it passes through the stomach, thereby avoiding many of the gastrointestinal effects associated with peripheral cholinesterase inhibition.
Human varicella-zoster immune globulin
go.drugbank.com/drugs/DB11621ApprovedInvestigationalThe therapeutic efficacy is proven if administered within 4 days of exposure to varicella zoster virus. … It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand … To extend the half-life of FVIII, efanesoctocog alfa is fused to dimeric Fc, a D'D3 domain of VWF, and two XTEN polypeptides.
Esculin
go.drugbank.com/drugs/DB13155ApprovedEsculin belongs to the family of Glycosyl Compounds. … ) and in daphnin (the dark green resin of Daphne mezereum).
Patisiran
go.drugbank.com/drugs/DB14582ApprovedIt is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … Evolocumab is the second PCSK9 inhibitor on the market, first being alirocumab.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … hormones from the anterior pituitary [T28].
Products: İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 FLAKON + 1 ÇÖZÜCÜ AMPULHexaminolevulinate
go.drugbank.com/drugs/DB06261ApprovedInvestigationalKarl Storz Photodynamic Diagnostic D-Light C (PDD) System for cystoscopic detection of non-muscle invasive papillary cancer of the bladder for patients suspected or known to have lesion(s) on the basis … Hexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®.